Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…
Chinese Scientists Discovered Strong Oncolytic Virus Synergist
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment of biomarkers. TheyRead More…
CAR-T for Autoimmune Disease and Blastoma Therapy
CAR-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…
The Application of CAR-T in Disease Treatment
Chimeric antigen receptor (CAR) modified T cells (CAR-T) as a new field of adoptive immune cell therapy has become a hot spot in recent research. In 1989, Israeli scholar Gross et al.Read More…
Carl June Published His Latest Paper: The Results of CAR-T Therapy Human Trials on the Treatment of Solid Tumors Shows Two Hurdles Still Need to Be Overcome!
In this month, FDA oncologic Drugs Advisory Committee agreed to the approval of Novartis’s CAR-T CTL019 therapy on a vote of 10:0 for the treatment of relapsed or refractory children and youngRead More…
Is Bio-distribution Study Necessary for CAR-T Therapy?
Biological therapy includes a variety of models, such as immunotherapy, gene therapy, regulation of angiogenesis therapy, small molecule targeting drugs and stem cells and tissue engineering regenerative medicine. Among them, cancer immunotherapyRead More…
Revelation! CAR-T Has Its “Eyes” on Solid Tumor and the Treatment of That Would Be Possible
Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimeric antigenRead More…
Comparison between CAR-T and TCR-T
As a matter of fact, tumor immunotherapy is divided into two categories. One is to show immune cells the tumor features, then direct them to locate and kill tumor cells. And anotherRead More…
A New Immunotherapy Called CAR-T Will Beat Cancer Surprisingly
CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifies humanRead More…
The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!
Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…